GAMMA Investing’s Candel Therapeutics CADL Stock Holding History

GAMMA Investing’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.4K	Buy	816 +567	+228%	+$4.28K	﹤0.01%	3289
2026 Q1	$1.22K	Sell	249 -46	-16%	-$250	﹤0.01%	3796
2025 Q4	$1.67K	Buy	295 +96	+48%	+$516	﹤0.01%	3659
2025 Q3	$1.01K	Buy	199 +166	+503%	+$959	﹤0.01%	3610
2025 Q2	$167	Sell	33 -153	-82%	-$787	﹤0.01%	3730
2025 Q1	$1.05K	Buy	186 +122	+191%	+$997	﹤0.01%	3550
2024 Q4	$556	Buy	64 +35	+121%	+$207	﹤0.01%	3558
2024 Q3	$201	Buy	+29	New	+$180	﹤0.01%	3498

Other funds holding CADL

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CSP

Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

LifeSteps Financial Claremont, California $215M AUM 27.52% 1-Year Est. Return

GAMMA Investing's CADL Position: Q2 2026 in Review

GAMMA Investing increased its Candel Therapeutics (CADL) stake by 228% in Q2 2026, buying an estimated $4.28K and bringing the position to 816 shares worth $8.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3289.

GAMMA Investing first reported a position in CADL in Q3 2024 and has held it in 8 quarters since. 6 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

GAMMA Investing held 816 shares of Candel Therapeutics worth $8.4K as of Q2 2026.
GAMMA Investing bought 567 Candel Therapeutics shares in Q2 2026, an estimated $4.28K.
Candel Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3289 holding.
GAMMA Investing first reported a position in Candel Therapeutics in Q3 2024 and has held it in 8 quarters since.
6 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.